Joo Ern Ang

3.6k total citations · 1 hit paper
50 papers, 2.0k citations indexed

About

Joo Ern Ang is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joo Ern Ang has authored 50 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 15 papers in Cancer Research and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joo Ern Ang's work include Cancer Genomics and Diagnostics (13 papers), PARP inhibition in cancer therapy (11 papers) and Ovarian cancer diagnosis and treatment (10 papers). Joo Ern Ang is often cited by papers focused on Cancer Genomics and Diagnostics (13 papers), PARP inhibition in cancer therapy (11 papers) and Ovarian cancer diagnosis and treatment (10 papers). Joo Ern Ang collaborates with scholars based in United Kingdom, Netherlands and Canada. Joo Ern Ang's co-authors include Johann S. de Bono, David Olmos, Stan B. Kaye, Florence I. Raynaud, Debra J. Skene, Victoria L. Revell, Alfred E. Thumser, Anúska Mann, Hendrik‐Tobias Arkenau and Ian Judson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Radiology.

In The Last Decade

Joo Ern Ang

48 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of sleep deprivation on the human metabolome

2014 387 citations Joo Ern Ang, Victoria L. Revell et al. profile →

Peers

Countries citing papers authored by Joo Ern Ang

Since Specialization

Citations

This map shows the geographic impact of Joo Ern Ang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joo Ern Ang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joo Ern Ang more than expected).

Fields of papers citing papers by Joo Ern Ang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joo Ern Ang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joo Ern Ang. The network helps show where Joo Ern Ang may publish in the future.

Co-authorship network of co-authors of Joo Ern Ang

This figure shows the co-authorship network connecting the top 25 collaborators of Joo Ern Ang. A scholar is included among the top collaborators of Joo Ern Ang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joo Ern Ang. Joo Ern Ang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Real-World Retrospective Observational Study of Patients with Advanced/Recurrent Endometrial Cancer Across England 2025 ·Oncology and Therapy ·(unknown), (unknown), (unknown), (unknown), (unknown), D. Schneider, (unknown), B. Mascialino, Kathryn Graham, Laura A. Tookman, René L. Roux, Joo Ern Ang	0
2	Non-contrast MRI can accurately characterize adnexal masses: a retrospective study 2021 ·European Radiology ·Hilal Şahin, Camilla Panico, Stephan Ursprung, Vittorio Simeon, Paolo Chiodini, Amy Frary, Bruno Carmo, Janette Smith, (unknown), Mercedes Jimenez‐Liñan, Helen Bolton, Krishnayan Haldar, Joo Ern Ang, Caroline Reinhold, Evis Sala, Helen Addley	26
3	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer? 2021 ·Seminars in Cancer Biology ·(unknown), Marika Reinius, Angelica Petrillo, Joo Ern Ang, James D. Brenton	12
4	Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials 2020 ·Clinical Cancer Research ·Angelika Terbuch, (unknown), (unknown), Mariana Scaranti, Andra Curcean, (unknown), (unknown), Malaka Ameratunga, Joo Ern Ang, Jonathan Ratoff, Anna Minchom, Udai Banerji, Johann S. de Bono, Nina Tunariu, Juanita Lopez	13
5	Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2) 2019 ·Investigational New Drugs ·Ruud van der Noll, Agnes Jager, Joo Ern Ang, Serena Marchetti, Marja Mergui‐Roelvink, Johann S. de Bono, Martijn P. Lolkema, Maja J.A. de Jonge, (unknown), André T. Brunetto, Hendrik‐Tobias Arkenau, Ilian Tchakov, Jos H. Beijnen, Jacques De Grève, Jan H.M. Schellens	10
6	Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials 2018 ·European Journal of Cancer ·Raghav Sundar, Terri McVeigh, David Dolling, Ann Petruckevitch, Nikolaos Diamantis, Joo Ern Ang, Maxime Chénard-Poirier, Dearbhaile Catherine Collins, Joline S.J. Lim, Malaka Ameratunga, Khurum Khan, Stan B. Kaye, Udai Banerji, Juanita Lopez, Angela George, Johann S. de Bono, Winette T.A. van der Graaf	6
7	Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma 2017 ·Molecular Cancer Therapeutics ·Joo Ern Ang, Ákos Pál, Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de Haven Brandon, Victoria L. Revell, Debra J. Skene, Miro Venturi, Ruediger Rueger, Valérie Méresse, Suzanne A. Eccles, Johann S. de Bono, Stanley B. Kaye, Paul Workman, Udai Banerji, Florence I. Raynaud	8
8	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study 2017 ·Clinical Colorectal Cancer ·(unknown), E. Goode, Francesco Sclafani, Joo Ern Ang, Marco Gerlinger, David González de Castro, Scott T.C. Shepherd, Clare Peckitt, Sheela Rao, David Watkins, Ian Chau, David Cunningham, Naureen Starling	46
9	Investigation of metabolites for estimating blood deposition time 2017 ·International Journal of Legal Medicine ·(unknown), Fan Liu, Sarah K. Davies, Katrin Ackermann, Joo Ern Ang, Benita Middleton, Victoria L. Revell, Florence I. Raynaud, Igor Hoveijn, Roelof A. Hut, Debra J. Skene, Manfred Kayser	13
10	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation 2016 ·Molecular Cancer Therapeutics ·Joo Ern Ang, (unknown), (unknown), Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de Haven Brandon, Richard D. Baird, Lori S. Friedman, Mika K. Derynck, Bart Vanhaesebroeck, Suzanne A. Eccles, Stan B. Kaye, Paul Workman, Johann S. de Bono, Florence I. Raynaud	16
11	First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·André T. Brunetto, Joo Ern Ang, Rohit Lal, David Olmos, L. Rhoda Molife, Rebecca Kristeleit, Ann Parker, (unknown), (unknown), (unknown), Bernhard Hauns, (unknown), (unknown), Johann S. de Bono	41
12	Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials 2012 ·Current Drug Targets ·Joo Ern Ang, Stan B. Kaye, Udai Banerji	23
13	Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer 2011 ·Journal of Clinical Oncology ·Stan B. Kaye, Jan Lubiński, Ursula A. Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y. Karlan, Amnon Amit, Katherine M. Bell‐McGuinn, Lee-may Chen, Michael Friedländer, Tamar Safra, Ignace Vergote, Mark Wickens, Elizabeth Lowe, James Carmichael, Bella Kaufman	378
14	A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: Unplanned admissions as an early indicator of patient attrition 2010 ·European Journal of Cancer ·André T. Brunetto, Joo Ern Ang, David Olmos, (unknown), Jorge Barriuso, Hendrik-Tobias Arkenau, Timothy A. Yap, L. Rhoda Molife, Udai Banerji, Johann S. de Bono, Ian Judson, Stan B. Kaye	11
15	A feasibility study of sequential doublet chemotherapy comprising carboplatin–doxorubicin and carboplatin–paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma 2009 ·Annals of Oncology ·Joo Ern Ang, Riyaz Shah, (unknown), (unknown), Ian Coombes, (unknown), Karen Thomas, Roger A’Hern, Robin L. Jones, Peter Blake, Hani Gabra, Geoff Hall, Martin Gore, Stan B. Kaye	10
16	CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer 2009 ·British Journal of Cancer ·Joo Ern Ang, David Olmos, Johann S. de Bono	84
17	Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? 2009 ·British Journal of Cancer ·Sophie Postel‐Vinay, (unknown), David Olmos, Joo Ern Ang, Jorge Barriuso, Sue Ashley, Udai Banerji, Johann S. de Bono, Ian Judson, S.B. Kaye	78
18	Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development 2008 ·Journal of Clinical Pathology ·Gerhardt Attard, Joo Ern Ang, David Olmos, Johann S. de Bono	9
19	Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience 2008 ·Annals of Oncology ·David Olmos, Hendrik‐Tobias Arkenau, Joo Ern Ang, Ioanna Ledaki, Gerhardt Attard, C. P. Carden, Alison Reid, Roger A’Hern, Peter C.C. Fong, (unknown), R. Molife, David P. Dearnaley, Chris Parker, Leon W.M.M. Terstappen, Johann S. de Bono	194
20	Ovarian Cancer: Can We Reverse Drug Resistance? 2008 ·Advances in experimental medicine and biology ·David S.P. Tan, Joo Ern Ang, Stan B. Kaye	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact